EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 &gt;50%

Chinelis, Panos; Efthymiou, Christofors; Athanasiadou, Anastasia; Mpikos, Vasilis; Papatsibas, George; Papadopoulos, Vasilis; Maragouli, Elena; Huang, Haidong; Trakada, Georgia; Kallianos, Anastasios; Veletza, Lemonia; Hohenforst-Schmidt, Wolfgang

doi:10.1016/j.rmcr.2017.05.010

Cited by 5 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation was attributed to the different patient selection [10] . In the case of a patient with both EGFR mutation and PD-L1 ≥50% tkis are currently advised [11] . Tyrosine kinase inhibitors have few and well controlled adverse effects [12] , [13] , [14] .…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

Athanasiou¹,

Tsiouda

Hatzibougias³

et al. 2017

Respiratory Medicine Case Reports

Self Cite

View full text Add to dashboard Cite

In this decade a “bloom” of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targeted therapies. Immunotherapy has been well established previously for other forms of cancer, and nowadays it is also available for lung cancer. There are two immunotherapies for now nivolumab and pembrolizumab which can be administered as second line treatment, the second can also be administered as first-line if there is a programmed death-ligand 1 ≥50% expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

Athanasiou¹,

Tsiouda

Hatzibougias³

et al. 2017

Respiratory Medicine Case Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are previous studies where regarding EGFR mutations we concluded that "tissue" is the issue, meaning that we might have acquired a sample from the tumor however not a part with PD-L1 expression or ≥50 PD-L1 expression which is the cut off measurement for first line single agent immunotherapy [30]. There are patients which very rarely present two mutations such as, EGFR and PD-L1, even in the case where PD-L1 expression is ≥50 then the patient should be treated with tyrosine kinase inhibitor [31]. Tumor molecular transformation has been also observed where patients without PD-L1 expression after surgery presented PD-L1 expression [13].…”

Section: Discussionmentioning

confidence: 99%

EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE^®

Sapalidis¹,

Petridis²,

Kosmıdis³

et al. 2019

J. Cancer

Self Cite

View full text Add to dashboard Cite

Introduction: Lung cancer is diagnosed at advanced stage due to lack of early disease symptoms. Currently we have several different biopsy techniques such as; radial endobronchial ultrasound, convex probe endobronchial ultrasound, electromagnetic navigation, ct guided biospy and transthoracic ultrasound biopsy. Novel therapies such as; immunotherapy is being used for non-small cell lung cancer in the everyday clinical practice as first and second line treatment. Programmed ligand-1 is essential in order to administer immunotherapy as first line treatment. Patients and Methods: Two thousands and two patients were included in our study where programmed ligand 1 was evaluated with DAKO technique and BIOCARE ®. Cell blocks were obtain with convex probe ebus-tbna 22G needle. Results: The Deming regression between DAKO and BIOCARE clone revealed an amazingly strong linear relationship as the coefficient of determination indicated (R 2 =0.999) and the variance ratio close to 1 (0.978), proving that both techniques can equally well be substituted for each other. The regression coefficient equals to 1 and the intercept hardly differs from 0 (0.936). In practice, this relationship permits adopting the economically affordable BIOCARE clone for further medical considerations. Conclusion: No statistical difference was observed between DAKO and BIOCARE ® , therefore we propose that both techniques can be used in order to investigate the expression of programmed ligand 1 with safety. PD-L1 expression was higher in the central mass instead of the lymphnodes.

show abstract

“…Furthermore, it has been previously observed that in the mutation for EGFR and KRAS and translocation/fusion for ALK, these genes play a role in the expression of PD-L1 in the case where the tumor expresses both 11. In this case, TKIs should be administered 12. It has been observed that a tumor might transform from adenocarcinoma to small-cell lung cancer (SCLC) or the main lesion might remain the same while metastatic sites might transform and then therapy has to change 13,14.…”

Section: Discussionmentioning

confidence: 99%

Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients

Kosmidis¹,

Koimtzis²,

Giannakidis³

et al. 2019

IMCRJ

Self Cite

View full text Add to dashboard Cite

Lung cancer is still diagnosed at a late stage although novel diagnostic techniques are in use. However, as pharmacogenomics have evolved novel targeted therapies either with tyrosine kinase inhibitors or immunotherapy can be currently used as daily treatment. We present the case of a woman with anaplastic lymphoma-positive expression and programmed death-ligand 1 (PD-L1) 0% score upon diagnosis who underwent therapeutic surgery and represented PD-L1 90% expression, however, without anaplastic lymphoma kinase expression. Transformation of the tumor or new tumor is a question to be answered for this patient and possibly we should try and direct rebiopsies for this group of targeted therapy patients.

show abstract

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

Cited by 5 publications

References 16 publications

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE^®

Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients

Contact Info

Product

Resources

About

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

Cited by 5 publications

References 16 publications

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®

Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients

Contact Info

Product

Resources

About

EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE^®